Overview
KRYS market data
Price History
KRYS price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for KRYS. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Krystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026Globenewswire Inc · Jul 23, 2026, 9:15 PM
Why Tutor Perini Stock Trounced the Market on TuesdayThe Motley Fool · Jul 21, 2026, 11:15 PM
Krystal Biotech Files Response With USPTO on KB801 Patent Application; Discontinues Clinical Study To Advance KB801 Into Pivotal Trial; No Safety Concerns Observed; No Further Subject-level Updates From Discontinued Study; Pivotal Trial Results Expected In Due CourseBenzinga · Jul 21, 2026, 9:33 PM
8-K filing — Krystal Biotech, Inc. (KRYS)SEC EDGAR · Jul 21, 2026, 9:24 PM
Krystal Biotech To Replace Taylor Morrison Home In The S&P MidCap 400, And Tutor Perini To Replace Krystal Biotech In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On Friday, July 24Benzinga · Jul 20, 2026, 9:18 PM
B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $396Benzinga · Jul 14, 2026, 2:18 PM
TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403Benzinga · Jun 18, 2026, 2:40 PM
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361Benzinga · Jun 16, 2026, 3:50 PM
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price TargetBenzinga · Jun 1, 2026, 11:06 AM
Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From BirthBenzinga · May 18, 2026, 12:10 PM